EUVIMEDEUVIMED entdecken
Crossref

Interleukin-33 as a central immune modulator of glymphatic dysfunction in Alzheimers disease - toward a unified immune-fluidic framework

Khaled A Abdel-Sater

Clinical review for general practice · 15.10.2026 · 7 (8) · 47-51

DOI: 10.47407/kr2026.7.8.00899 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical review for general practice, online erschienen am 15.10.2026. Verfasst von Khaled A Abdel-Sater.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alzheimer’s disease (AD) remains without effective disease-modifying therapy despite decades of amyloid- and tau-focused interventions. Increasing evidence indicates that diverse pathological processes – including neuroinflammation, astrocytic dysfunction, vascular impairment, and immune dysregulation – converge on a common downstream failure: disruption of glymphatic clearance. However, the immune signals that regulate astrocytic polarity and perivascular fluid transport remain poorly defined.

Aim

To advance a unified immune-fluidic framework positioning interleukin-33 (IL-33) as a central upstream regulator linking neuroimmune signaling to glymphatic dysfunction in AD.

Methods

This narrative review integrates experimental, genetic, biomarker, and translational studies examining IL-33/ST2 signaling, astrocytic aquaporin-4 (AQP4) polarization, microglial reprogramming, and cerebrospinal-interstitial fluid exchange in aging and AD.

Results

IL-33 emerges as a critical regulator of perivascular AQP4 localization rather than total AQP4 expression, thereby governing glymphatic flux and metabolic waste clearance. Experimental IL-33 deficiency leads to astrocytic depolarization, impaired glymphatic drainage, and accelerated amyloid-β and tau accumulation, whereas restoration of IL-33 signaling rescues perivascular architecture and clearance efficiency. IL-33 further orchestrates PU.1-dependent microglial phenotypic shifts, supports mitochondrial and autophagic homeostasis, and operates within a cytokine-competitive signaling network influenced by age, sex, and APOE genotype.

Conclusion

Positioning IL-33 as a master immune-fluidic regulator reframes AD as a disorder of coordinated clearance failure rather than isolated proteinopathy. Therapeutic strategies targeting the IL-33-glymphatic axis may offer disease-modifying potential independent of direct amyloid or tau reduction. Keywords: interleukin-33, glymphatic system, astrocytic aquaporin-4, neuroimmune regulation, Alzheimer’s disease.

Zitieren

APA

Abdel-Sater, K. A. (2026). Interleukin-33 as a central immune modulator of glymphatic dysfunction in Alzheimers disease - toward a unified immune-fluidic framework. Clinical review for general practice, 7(8), 47-51. https://doi.org/10.47407/kr2026.7.8.00899

Vancouver

Abdel-Sater KA. Interleukin-33 as a central immune modulator of glymphatic dysfunction in Alzheimers disease - toward a unified immune-fluidic framework. Clinical review for general practice. 2026;7(8):47-51. doi:10.47407/kr2026.7.8.00899

BibTeX
@article{AbdelSater2026,
  author = {Abdel-Sater, Khaled A},
  title = {Interleukin-33 as a central immune modulator of glymphatic dysfunction in Alzheimers disease - toward a unified immune-fluidic framework},
  journal = {Clinical review for general practice},
  year = {2026},
  volume = {7},
  number = {8},
  pages = {47--51},
  doi = {10.47407/kr2026.7.8.00899}
}
Kostenlos starten →